ReviewCancer gene therapy2015
Manufacture of T cells using the Sleeping Beauty system to enforce expression of a CD19-specific chimeric antigen receptor.
Review in Cancer gene therapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 77 citations in OpenAlex.
- CAR-T Cell Therapy: Pioneering Immunotherapy Paradigms in Cancer Treatment.Current pharmaceutical biotechnology · 2026Review
- INSPIRED Symposium Part 4B: Chimeric Antigen Receptor T Cell Correlative Studies-Established Findings and Future Priorities.Transplantation and cellular therapy · 2024Review
- Manufacturing CD20/CD19-targeted iCasp9 regulatable CAR-TSCM cells using a Quantum pBac-based CAR-T engineering system.PloS one · 2024Article
- A Nonviral piggyBac Transposon-Mediated Method to Generate Large-Scale CAR-NK Cells from Human Peripheral Blood Primary NK Cells.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Updates on global epidemiology, risk and prognostic factors of gastric cancer.World journal of gastroenterology · 2023Review
- Review
- Microphysiological systems for solid tumor immunotherapy: opportunities and challenges.Microsystems & nanoengineering · 2023Review
- Current strategies employed in the manipulation of gene expression for clinical purposes.Journal of translational medicine · 2022Review
- CAR-T cell potency: from structural elements to vector backbone components.Biomarker research · 2022Review
- Chimeric Antigen Receptor T-Cells: An Overview of Concepts, Applications, Limitations, and Proposed Solutions.Frontiers in bioengineering and biotechnology · 2022Review
- piggyBac system to co-express NKG2D CAR and IL-15 to augment theMolecular therapy. Methods & clinical development · 2021Article
- T Cell Engaging Immunotherapies, Highlighting Chimeric Antigen Receptor (CAR) T Cell Therapy.Cancers · 2021Review
- CAR T cell therapy as a promising approach in cancer immunotherapy: challenges and opportunities.Cellular oncology (Dordrecht, Netherlands) · 2021Review
- A nonviral, nonintegrating DNA nanovector platform for the safe, rapid, and persistent manufacture of recombinant T cells.Science advances · 2021Article
- Designed improvement to T-cell immunotherapy by multidimensional single cell profiling.Journal for immunotherapy of cancer · 2021Article
- CAR T-Cell Production Using Nonviral Approaches.Journal of immunology research · 2021Review
- Mechanisms of resistance to CAR T cell therapies.Seminars in cancer biology · 2020Review
- CAR T Cells: A Snapshot on the Growing Options to Design a CAR.HemaSphere · 2019Review
- Novel biomanufacturing platform for large-scale and high-quality human T cells production.Journal of biological engineering · 2019Article
- Emerging trends in the immunotherapy of pancreatic cancer.Cancer letters · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
T cells can be reprogrammed to redirect specificity to tumor-associated antigens (TAAs) through the enforced expression of chimeric antigen receptors (CARs). The prototypical CAR is a single-chain molecule that docks with TAA expressed on the cell surface and, in contrast to the T-cell receptor complex, recognizes target cells independent of human leukocyte antigen. The bioprocessing to generate CAR(+) T cells has been reduced to clinical practice based on two common steps that are accomplished in compliance with current good manufacturing practice. These are (1) gene transfer to stably integrate the CAR using viral and nonviral approaches and (2) activating the T cells for proliferation by crosslinking CD3 or antigen-driven numeric expansion using activating and propagating cells (AaPCs). Here, we outline our approach to nonviral gene transfer using the Sleeping Beauty system and the selective propagation of CD19-specific CAR(+) T cells on AaPCs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.